United Laboratories International Holdings Ltd 2024 SR
The report highlights The United Laboratories' commitment to pharmaceutical R&D, investing RMB 986 million in 2024. It details progress in medical accessibility, with 67 products in the National Medical Insurance List, and environmental stewardship, achieving zero wastewater discharge at its Inner Mongolia production base. The company also emphasizes social responsibility through its "Filial Piety Swallows" charity and employee development, maintaining a 37.1% female management ratio.
Company: United Laboratories International Holdings Ltd
Sector: Health Care
Country: Hong Kong
Year: 2024
Type: SR
Pages: 118
United Laboratories International Holdings Ltd
ESG Report
The report highlights The United Laboratories' commitment to pharmaceutical R&D, investing RMB 986 million in 2024. It details progress in medical accessibility, with 67 products in the National Medical Insurance List, and environmental stewardship, achieving zero wastewater discharge at its Inner Mongolia production base. The company also emphasizes social responsibility through its "Filial Piety Swallows" charity and employee development, maintaining a 37.1% female management ratio.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Published
Apr 23, 2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees